Category

Archives

Blog of Signaling Pathways

Thermal proteome profiling identifies PIP4K2A and ZADH2 as off-targets of Polo-like kinase 1 inhibitor volasertib

409 views | Aug 15 2021

Oksana Goroshchuk et al. suggested that PIP4K2A was a true off-target of volasertib. [Read the Full Post]

Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer

292 views | Aug 13 2021

Stefan Prekovic et al. showed that GR activation induced reversible cancer cell dormancy characterised by anticancer drug tolerance, and activation of growth factor survival signalling accompanied by vulnerability to inhibitors. [Read the Full Post]

A Precision Medicine Approach to Optimize Modulator Therapy for Rare CFTR Folding Mutants

277 views | Aug 13 2021

Guido Veit et al. thought that HNE, as a precision medicine model, enabled the optimization of mutation-specific modulator combinations to maximize their efficacy and minimize life-long drug exposure of CF patients. [Read the Full Post]

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

444 views | Aug 12 2021

Alexander J Stratigos et al. found that cemiplimab exhibited clinically meaningful antitumour activity and an acceptable safety profile in patients with locally advanced basal cell carcinoma after HHI therapy. [Read the Full Post]

A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection

273 views | Aug 12 2021

Fangyuan Chen et al. found that almeterol, rottlerin, and mTOR inhibitors exhibited antiviral activities in Vero-E6 cells; imipramine, linsitinib, hexylresorcinol, ezetimibe, and brompheniramine impaired viral entry. [Read the Full Post]

Sinus rhythm heart rate increase after atrial fibrillation ablation is associated with lower risk of arrhythmia recurrence

794 views | Aug 11 2021

Ammar M Killu et al. showed that relative changes in HR post AF ablation correlates with AF recurrence. [Read the Full Post]

Interpretable deep recommender system model for prediction of kinase inhibitor efficacy across cancer cell lines

319 views | Aug 11 2021

Krzysztof Koras et al. proposed a novel interpretability approach, which in addition to the set of modeled features consideres also the genes and processes outside of this set. [Read the Full Post]

Efficacy and Safety of Emricasan in Liver Cirrhosis and/or Fibrosis

623 views | Aug 10 2021

Li-Ya Mu et al. found that treatment with emricasan was more effective in improving liver function and apoptosis parameters compared to placebo, with a well-tolerated safety profile. [Read the Full Post]

Effects of combination treatment with transcranial magnetic stimulation and bone marrow mesenchymal stem cell transplantation or Raf inhibition on spinal cord injury in rats

269 views | Aug 10 2021

Sining Feng et al. thought that compared with monotherapy, combination therapy displayed an improved therapeutic effect on SCI by further suppressing Raf/MEK/ERK signaling. [Read the Full Post]

MLN4924 inhibits hedgehog signaling pathway and activates autophagy to alleviate mouse laser-induced choroidal neovascularization lesion

420 views | Aug 09 2021

Laiqing Xie et al. found that MLN4924 relieved the formation of mouse laser-induced CNV lesion might via up-regulating hedgehog pathway-regulated autophagy. [Read the Full Post]

Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib

1197 views | Aug 09 2021

Neslihan Büküm et al. demonstrated that dasatinib could synergize with Daun in human cancer cells and enhance its therapeutic effectiveness. [Read the Full Post]

Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer

894 views | Aug 08 2021

Tiziana Feola et al. provided an overview of the predictive factors for the response and survival of sorafenib and lenvatinib in RR-DTC. [Read the Full Post]

Verticillin A increases the BIM EL/MCL-1 ratio to overcome ABT-737-resistance in human colon cancer cells by targeting the MEK/ERK pathway

391 views | Aug 08 2021

Yuelin Guan et al. suggested the potential application of Verticillin A as a MEK inhibitor in BH3-mimetic-based therapy. [Read the Full Post]

HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer

782 views | Aug 06 2021

Miranda E Clements et al. suggested HDACi as a potential therapeutic avenue to promote dormancy, prevent recurrence, and improve patient outcomes in breast cancer. [Read the Full Post]

Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer

841 views | Aug 06 2021

Jiani Wang et al. found that entinostat with exemestane showed reasonable safety, tolerability, and encouraging efficacy in Chinese patients with HR+/HER2- MBC. [Read the Full Post]

Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

197 views | Aug 05 2021

Grégoire Marret et al. found that copanlisib combined with cetuximab demonstrated unfavorable toxicity and limited efficacy in heavily pretreated recurrent and/or metastatic HNSCC patients. [Read the Full Post]

Inhibition of TLR4 prevents hippocampal hypoxic-ischemic injury by regulating ferroptosis in neonatal rats

477 views | Aug 05 2021

Kaiyi Zhu et al. demonstrated that the inhibition of TLR4-p38 MAPK signaling modulated HIBD- or OGD-induced ferroptosis in neuronal cells and might play a novel role in brain homeostasis. [Read the Full Post]

Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome

301 views | Aug 04 2021

Cheng Zhang et al. thought that CDK4/6 inhibitors including abemaciclib, ribociclib and palbociclib as potential therapeutic targets and might help for therapeutic decision making. [Read the Full Post]

ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors

218 views | Aug 04 2021

Ana Portelinha et al. found that the PI3K inhibitor copanlisib enhanced the antiproliferative activity of ASN007 both in vitro and in vivo due to dual inhibition of RAS/MAPK and PI3K survival pathways. [Read the Full Post]

Local ablation of gastric cancer by reconstituted apolipoprotein B lipoparticles carrying epigenetic drugs

1000 views | Aug 03 2021

Chia-Lung Yang et al. established rABL-based nanoparticles embedded epigenetic inhibitors for local treatment of gastric cancer, which had good therapeutic effects but do not cause severe side effects. [Read the Full Post]